Inhibition of platelet aggregation in whole blood by adrenoceptor antagonists.
It has recently become possible to study platelet aggregation in whole blood which may more closely resemble the in-vivo situation as the platelets are left in their natural milieu with red and white cells present which themselves can influence aggregation. The effects of 4 adrenoceptor antagonists on platelet aggregation in whole blood were studied in-vitro using the Clay-Adams Ultra Flo 100 whole blood platelet counter. Labetalol, pindolol and propranolol inhibited aggregation to 0.5 microgram/ml collagen in a dose dependent manner, and were synergistic with prostacyclin in inhibiting collagen induced aggregation. These 3 drugs also promoted reversal of aggregation induced by 10 microM ADP, but only inhibited 0.5 mM arachidonic acid induced aggregation at high drug concentrations. Atenolol had no effect on either collagen, ADP or arachidonic acid induced aggregation. The anti-platelet effect of these drugs may be of value in the treatment of vascular disease.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000494:pharmacology; D001262:Atenolol / Q000494:pharmacology; D003094:Collagen / Q000494:pharmacology; D004357:Drug Synergism; D011464:Epoprostenol / Q000494:pharmacology*; D006801:Humans; D007741:Labetalol / Q000494:pharmacology; D010869:Pindolol / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects*; D011433:Propranolol / Q000494:pharmacology; D012995:Solubility; D013565:Sympatholytics / Q000494:pharmacology*
D001095:Arachidonic Acids; D013565:Sympatholytics; D016718:Arachidonic Acid; D001262:Atenolol; D000244:Adenosine Diphosphate; D003094:Collagen; D011433:Propranolol; D010869:Pindolol; D011464:Epoprostenol; D007741:Labetalol